# Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting
Canonical URL: https://biopharmsignal.com/news/NRIX/nurix-therapeutics-presents-new-preclinical-and-phase-1-translational-data-supporting-bexobrutideg-nx-5948-in-chronic-spontaneous-urticaria-at-the-2026-society-for-investigative-dermatology-annual-meeting
Ticker: NRIX
Company: Nurix Therapeutics
Source: Nurix Therapeutics
Published: 2026-05-14 20:06 EST
Original Source URL: https://ir.nurixtx.com
## Summary

In preclinical studies of CSU, Bexobrutideg demonstrates potent BTK degradation across key immune cell types and enhanced suppression of FcεRI-driven pathology versus remibrutinib In healthy volunteers, both single- and multiple-ascending-dose oral dosing of bexobrutideg led to rapid and robust BTK

## Article Body
In preclinical studies of CSU, Bexobrutideg demonstrates potent BTK degradation across key immune cell types and enhanced suppression of FcεRI-driven pathology versus remibrutinib In healthy volunteers, both single- and multiple-ascending-dose oral dosing of bexobrutideg led to rapid and robust BTK
## Recent Company News
- 2026-05-14 20:06 EST — [Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-presents-new-preclinical-and-phase-1-translational-data-supporting-bexobrutideg-nx-5948-in-chronic-spontaneous-urticaria-at-the-2026-society-for-investigative-dermatology-annual-meeting) — Source: Nurix Therapeutics
- 2026-05-13 11:00 EST — [Nurix Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-to-participate-in-upcoming-investor-conferences) — Source: Nurix Therapeutics
- 2026-05-12 20:05 EST — [Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-announces-bexobrutideg-oral-presentation-at-the-2026-european-hematology-association-congress) — Source: Nurix Therapeutics
- 2026-04-22 11:00 EST — [Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-announces-new-preclinical-data-highlighting-breadth-of-targeted-protein-degradation-pipeline-at-aacr-2026) — Source: Nurix Therapeutics
- 2026-04-08 10:00 EST — [Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-reports-first-quarter-2026-financial-results-and-provides-a-corporate-update) — Source: Nurix Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)